Download video

IMpassion130 and IMpassion131: The difference a taxane makes? | Leisha Emens

692 views

Medicine Matters oncology

4 years ago

IMpassion130 and IMpassion131: The difference a taxane makes? | Leisha Emens

IMpassion130 and IMpassion131: The difference a taxane makes? | Leisha Emens

IMpassion130 and IMpassion131: The difference a taxane makes? | Leisha Emens
2:20
IMpassion130 and IMpassion131: The difference a taxane makes? | Leisha Emens
by Medicine Matters oncology
IMpassion130: Atezolizumab and nab-paclitaxel in triple-negative breast cancer
5:59
IMpassion130: Atezolizumab and nab-paclitaxel in triple-negative breast cancer
by ecancer
Elizabeth Mittendorf, MD, PhD, on the implications of the IMpassion-130 and IMpassion-131 trials
2:19
Elizabeth Mittendorf, MD, PhD, on the implications of the IMpassion-130 and IMpassion-131 trials
by OBRoncology
IMpassion130 Data Demonstrate Clinical Benefit for Immunotherapy in Metastatic TNBC
0:59
IMpassion130 Data Demonstrate Clinical Benefit for Immunotherapy in Metastatic TNBC
by Targeted Oncology
IMpassion130: results of atezolizumab plus nab-paclitaxel for frontline TNBC
7:08
IMpassion130: results of atezolizumab plus nab-paclitaxel for frontline TNBC
by VJOncology
IMPassion130: atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naiv...
4:15
IMPassion130: atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naiv...
by Oncoletter
ESMO 2020 Expert Video report on atezolizumab in upfront treatment of TNBC
7:36
ESMO 2020 Expert Video report on atezolizumab in upfront treatment of TNBC
by European Society for Medical Oncology (ESMO)
Breast cancer at ESMO 2020: IMpassion131, SOLAR-1, PALLAS and more
3:50
Breast cancer at ESMO 2020: IMpassion131, SOLAR-1, PALLAS and more
by VJOncology
Immunotherapy for TNBC: IMpassion130 \& KEYNOTE-355
4:11
Immunotherapy for TNBC: IMpassion130 \& KEYNOTE-355
by VJOncology
AGO-OVAR 2.29\/ENGOT-ov34: atezolizumab vs placebo + bevacizumab w\/ chemo recurrent ovarian cancer
6:10
AGO-OVAR 2.29\/ENGOT-ov34: atezolizumab vs placebo + bevacizumab w\/ chemo recurrent ovarian cancer
by VJOncology
Performance of PD-L1 IHC assays in IMpassion130: a post-hoc analysis
4:46
Performance of PD-L1 IHC assays in IMpassion130: a post-hoc analysis
by VJOncology
Dr. Emens on the Future of Immunotherapy in Ovarian Cancer
0:50
Dr. Emens on the Future of Immunotherapy in Ovarian Cancer
by OncLive
IMpassion130: Design and Preliminary Efficacy
2:51
IMpassion130: Design and Preliminary Efficacy
by OncLive
Chemoimmunotherapy in TNBC: The IMpassion130 Trial
8:42
Chemoimmunotherapy in TNBC: The IMpassion130 Trial
by OncLive
Case 3: Results of the IMpassion130 Trial in Metastatic Breast Cancer
6:33
Case 3: Results of the IMpassion130 Trial in Metastatic Breast Cancer
by Targeted Oncology
IMpassion130: immunotherapy for TNBC
2:30
IMpassion130: immunotherapy for TNBC
by VJOncology
Results from the IMpassion 130 trial treating metastatic breast cancer
4:56
Results from the IMpassion 130 trial treating metastatic breast cancer
by ecancer
The IMpassion130 Study in Metastatic TNBC
4:27
The IMpassion130 Study in Metastatic TNBC
by Targeted Oncology
IMpassion130: Implications
1:00
IMpassion130: Implications
by VJOncology
IMpassion130 Trial: OS Updates in Metastatic TNBC
7:19
IMpassion130 Trial: OS Updates in Metastatic TNBC
by OncLive
IMpassion130 Trial Data on PD-L1+ Tumors in TNBC
6:56
IMpassion130 Trial Data on PD-L1+ Tumors in TNBC
by OncLive
Applying IMpassion130 Data to TNBC Management
2:33
Applying IMpassion130 Data to TNBC Management
by OncLive
Results from the IMpassion130 trial for triple-negative breast cancer
4:53
Results from the IMpassion130 trial for triple-negative breast cancer
by ecancer